In a reader survey, researchers and core lab staff share how they think cores are doing.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Researchers are working on RNA inference-based pesticides for crops, according to Digital Trends.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.
The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.
Researchers described the development and testing of layered double hydroxide nanosheets as carriers for RNAi molecules in agriculture.
An Australian team has developed a method to spray double-stranded RNA on plants to make them resistant to pests, Technology Review reports.
The researchers said their one-step, inducible, multiplex gene knockdown and gene knockout platforms can be used in many differentiated cell types.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.